For parents, a child’s digestive health is often a source of worry, from occasional upset stomachs to the more concerning sight of blood in the stool. Although often linked to minor infections or dietary changes, such symptoms can sometimes signal a more serious underlying condition. A recent case involving a three-year-ancient boy highlights the importance of investigating persistent gastrointestinal issues, even when initial tests are inconclusive, and the growing recognition of very early onset inflammatory bowel disease (VEOIBD).
The young patient presented to the emergency department with three weeks of progressively worsening hematochezia – bright red blood in the stool. What began as occasional spotting quickly escalated to up to ten bloody bowel movements daily, accompanied by loose stools and, crucially, fecal incontinence. This combination of symptoms prompted a deeper investigation, ultimately leading to a diagnosis of VEOIBD, a rare but increasingly identified subset of pediatric inflammatory bowel disease.
Early Symptoms and Initial Investigations
Initial tests conducted by the child’s primary care physician ruled out common causes of bloody stool, including infections from Giardia, E. Coli, and elevated levels of fecal lactoferrin, a marker of intestinal inflammation. There was no indication of recent travel, dietary changes, or a family history of gastrointestinal disorders. Despite these negative results, the frequency and severity of the bleeding prompted a visit to the emergency department.
Upon arrival, laboratory tests revealed a hemoglobin level of 8.3 g/dL, indicating anemia likely due to blood loss. His platelet count was 536,000/µL, C-reactive protein (CRP) measured 5.3 mg/L, erythrocyte sedimentation rate (ESR) was 33 mm/hr, and procalcitonin was 1.34 ng/mL. Further stool tests, including a comprehensive enteric pathogen panel and a test for Clostridioides difficile (C. Diff), were also negative. An abdominal ultrasound showed possible proctitis, or inflammation of the rectum, but was otherwise normal.
Diagnosis and Treatment
Given the persistent concern for colitis, specialists in gastroenterology were consulted for an urgent endoscopic evaluation. The patient was admitted to the hospital and started on intravenous methylprednisolone and pantoprazole, medications used to reduce inflammation and stomach acid, respectively. Elemental iron supplementation was also initiated to address the anemia. In anticipation of potential future therapies, tests for Quantiferon Gold and hepatitis B were ordered.
A colonoscopy revealed severe pancolitis, meaning inflammation throughout the entire colon, but the ileum – the final section of the small intestine – appeared normal. A concurrent upper endoscopy (EGD) showed a healthy esophagus, stomach, and duodenum, with only minor areas of mild redness. The patient responded well to the initial treatment with methylprednisolone and pantoprazole, and was discharged home with a plan for continued outpatient care, including oral prednisone and iron supplementation.
Understanding Very Early Onset IBD
VEOIBD is defined as inflammatory bowel disease diagnosed before the age of six, and it’s becoming increasingly recognized as a distinct category within pediatric IBD. According to research, it often presents with extensive colitis, can involve unusual symptoms beyond the digestive system, and may be less responsive to standard treatments. Advances in genetic testing are playing a crucial role in understanding and managing this condition.
Whole exome sequencing – a method of mapping a person’s entire genetic code – has identified mutations in genes related to IL-10 signaling, epithelial barrier function, and T-cell regulation as potential drivers of VEOIBD. Specifically, mutations in genes such as IL10RA/B, XIAP, and FOXP3 have been linked to the disease. Researchers are also investigating the role of imbalances in the gut microbiome – the community of microorganisms living in the digestive tract – and dysfunction of the innate immune system in the development of VEOIBD.
The case of this three-year-old boy underscores the importance of considering VEOIBD even when initial investigations are unrevealing. Early detection and tailored treatment strategies are critical for managing this complex condition and improving outcomes for young patients. Future research will focus on identifying additional genetic factors, refining microbiome-targeted therapies, and understanding how early life experiences influence disease onset, and progression.
This case reinforces the need for vigilance and a comprehensive approach to diagnosing and treating gastrointestinal issues in young children. If you are concerned about your child’s digestive health, it is important to consult with a healthcare professional.
Disclaimer: The information provided in this article is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
